The GLP-1 weight-loss drug market is undergoing rapid reshuffling. Novo Nordisk pioneered the sector in 2017, but Eli Lilly has since pulled ahead to capture 60% of the U.S. market and secure industry leadership. Fueled by the sector’s lucrative potential, a growing number of drugmakers are entering the space. Among new entrants, Viking Therapeutics (VKTX) has drawn intense market attention, with investors questioning whether the biotech can replicate Lilly’s breakout growth and join the industry’s top tier.
Novo Nordisk founded the modern weight-loss drug market with its GLP-1 treatment, initially approved for type 2 diabetes. The drug gained widespread off-label use for weight loss before securing official obesity approval, establishing the firm’s early market dominance. While Novo Nordisk solidified its position, Lilly accelerated its expansion. Its weight-loss portfolio delivered strong clinical results and robust quarterly revenue, overtaking the industry veteran and resetting the market hierarchy.
To defend their dominance, both Lilly and Novo Nordisk have expanded their product lines with newly launched oral weight-loss drugs, strengthening their product portfolios and brand moats. Industry projections estimate the global weight-loss drug market will near $100 billion by the end of the decade, leaving ample growth room for emerging biotech players.
Viking’s core growth catalyst is its pipeline candidate VK2735, a dual GLP-1/GIP receptor agonist with a mechanism identical to Lilly’s flagship weight-loss drugs. The compound regulates appetite and blood sugar to drive weight reduction. Uniquely, Viking is developing both injectable and oral formulations of VK2735, making it the only dual-formula candidate in its class and delivering a clear competitive edge.
The injectable version is currently in Phase 3 trials, while the oral variant is on track to begin Phase 3 testing in the fourth quarter of 2025. Phase 2 data demonstrated robust weight-loss efficacy, matching the performance of marketed products from Lilly and Novo Nordisk and proving VK2735’s capacity for head-to-head market competition.
Despite strong early efficacy, Viking faces material barriers to challenging Lilly’s leadership. Safety concerns represent the biggest hurdle. High-dose VK2735 triggered frequent gastrointestinal side effects in Phase 2 trials, leading to high treatment discontinuation rates and exposing weak drug tolerability. The firm must optimize dosages and gradual titration strategies in Phase 3 trials to balance efficacy and safety for regulatory approval.
Structural corporate disadvantages further limit Viking’s upside. As a mature pharmaceutical giant, Lilly boasts established brand credibility, large-scale manufacturing capacity and comprehensive commercial channels. In contrast, Viking remains a clinical-stage biotech with no revenue and persistent losses, lagging far behind industry leaders in capital, production capabilities and clinical recognition. Intensifying competition from new industry entrants adds further pressure.
Viking is unlikely to dethrone Lilly in the near term. Lilly maintains a solid market position and a rich drug pipeline, creating high barriers for small biotechs seeking market disruption.
Even without claiming industry leadership, Viking still holds substantial commercial potential. If VK2735 completes clinical trials and gains regulatory approval, its dual-formula advantage will allow it to capture meaningful niche market share. A successful launch would drive significant upside for the company’s revenue and stock price.
The stock carries balanced risk and reward. Uncertain clinical outcomes and intensifying industry competition could trigger sharp share volatility, making it suitable only for investors with high risk tolerance.
The weight-loss drug market has evolved from a Lilly-Novo Nordisk duopoly into a multi-competitor landscape. While incumbents retain solid advantages, emerging players continue to disrupt the market. Viking’s promising candidate grants it top-tier breakthrough potential, yet the firm must overcome clinical safety, commercialization and competitive challenges to move up the industry ranks. Upcoming trial data and launch progress will define its long-term market position.
